Stock 4133 ABNOVA (TAIWAN) CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials Abnova (Taiwan) Corporation

Equities

4133

TW0004133004

Biotechnology & Medical Research

End-of-day quote Taiwan S.E.
Other stock markets
 06:00:00 2024-05-23 pm EDT 		5-day change 1st Jan Change
32.1 TWD -0.31% Intraday chart for Abnova (Taiwan) Corporation +1.26% -8.55%
May. 09 Abnova Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
May. 08 Abnova Corporation Announces Establishment of Risk Management Committee CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 1,817 1,538 3,524 2,637 2,495 2,125
Enterprise Value (EV) 1 1,672 1,389 3,286 2,346 2,139 1,710
P/E ratio 39.5 x 508 x 97 x 93 x 33.5 x 48.8 x
Yield 2% 0.39% 1.03% 1.06% 1.94% 2.05%
Capitalization / Revenue 4.26 x 3.71 x 7.72 x 5.84 x 6.06 x 5.56 x
EV / Revenue 3.92 x 3.35 x 7.2 x 5.2 x 5.2 x 4.48 x
EV / EBITDA 35.8 x 45.9 x 40.2 x 35.2 x 26.2 x 26.6 x
EV / FCF 34 x 18.1 x 32 x 24.2 x -588 x 19.1 x
FCF Yield 2.94% 5.51% 3.12% 4.13% -0.17% 5.24%
Price to Book 1.48 x 1.29 x 2.91 x 2.18 x 1.93 x 1.65 x
Nbr of stocks (in thousands) 60,554 60,554 60,554 60,554 60,554 60,554
Reference price 2 30.00 25.40 58.20 43.55 41.20 35.10
Announcement Date 3/27/19 3/27/20 3/31/21 3/21/22 3/1/23 2/29/24
1TWD in Million2TWD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 426 414.2 456.4 451.5 411.8 382.1
EBITDA 1 46.74 30.25 81.84 66.58 81.76 64.2
EBIT 1 20.16 2.644 57.67 43.82 64.43 47.19
Operating Margin 4.73% 0.64% 12.63% 9.71% 15.65% 12.35%
Earnings before Tax (EBT) 1 37.11 0.98 49.05 36.29 94.96 48.52
Net income 1 46.12 3.263 36.53 28.37 74.84 43.68
Net margin 10.83% 0.79% 8% 6.28% 18.18% 11.43%
EPS 2 0.7600 0.0500 0.6000 0.4685 1.230 0.7200
Free Cash Flow 1 49.24 76.59 102.6 96.88 -3.638 89.53
FCF margin 11.56% 18.49% 22.47% 21.46% -0.88% 23.43%
FCF Conversion (EBITDA) 105.34% 253.22% 125.35% 145.52% - 139.44%
FCF Conversion (Net income) 106.76% 2,347.26% 280.85% 341.51% - 204.98%
Dividend per Share 2 0.6000 0.1000 0.6000 0.4600 0.8000 0.7200
Announcement Date 3/27/19 3/27/20 3/31/21 3/21/22 3/1/23 2/29/24
1TWD in Million2TWD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 145 149 238 291 356 415
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 49.2 76.6 103 96.9 -3.64 89.5
ROE (net income / shareholders' equity) 3.76% 0.27% 3.04% 2.34% 5.98% 3.39%
ROA (Net income/ Total Assets) 0.97% 0.13% 2.82% 2.13% 3.03% 2.16%
Assets 1 4,757 2,527 1,296 1,335 2,470 2,022
Book Value Per Share 2 20.30 19.70 20.00 20.00 21.30 21.20
Cash Flow per Share 2 2.390 2.760 4.260 5.070 6.060 6.990
Capex 1 33.1 4.91 3.22 0.73 1.39 19.6
Capex / Sales 7.78% 1.18% 0.71% 0.16% 0.34% 5.12%
Announcement Date 3/27/19 3/27/20 3/31/21 3/21/22 3/1/23 2/29/24
1TWD in Million2TWD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ABNOVA (TAIWAN) CORPORATION Stock Abnova (Taiwan) Corporation
-8.55% 60.44M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+12.11% 116B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+12.56% 106B
BIONTECH SE Stock BioNTech SE
-10.05% 23.89B
ARGENX SE Stock argenx SE
-1.69% 21.58B
GENMAB A/S Stock Genmab A/S
-10.60% 18.96B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.25% 16.96B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.59% 16.33B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.03% 14.14B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+29.76% 12.02B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 4133 Stock
  4. Financials Abnova (Taiwan) Corporation